Incremental benefit of sodium–glucose cotransporter 2 inhibitor and mineralocorticoid receptor antagonist therapy in HFpEF with moderate mitral regurgitation: 24-month ambulatory cohort study

29 August 2026 (10:15 - 11:00)
Organised by: Logo
Congress Presentation Part of: Heart failure: drugs, diagnosis, and demographics Heart Failure with Preserved Ejection Fraction (HFpEF) ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology